Aspergillosis Treatment Market By Disease Type (Invasive Aspergillosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis); By Treatment Type (Triazole Antifungals, Polyenes, Echinocandins and Combination/Salvage Therapy, Corticosteroid-Based ABPA Therapy, Emerging Antifungal Therapies); By End User (Hospitals, Transplant and Oncology Centers, Pulmonary and Respiratory Specialty Clinics, Infectious Disease Specialty Clinics); By Region, Segment Revenue Estimation, Forecast, 2026–2032

Aspergillosis Treatment Market: Resistance, Hospital Risk, and Faster Diagnosis Reshape Antifungal Demand

The Global Aspergillosis Treatment Market was valued at USD 4.3 billion in 2025 and is projected to reach USD 6.17 billion by 2032, growing at a CAGR of 5.27%, according to Strategic Market Research.

 

Aspergillosis is being diagnosed more often in hospital settings, particularly among transplant recipients, hematology patients, immunocompromised individuals, and people with chronic respiratory disease. In a U.S. EHR study of more than 76 million adults across 142 health systems, 20,764 patients had aspergillosis. Recorded prevalence rose by about 5% per year between 2013 and 2023.

 

Aspergillosis treatment demand differs by disease type. Invasive cases are managed in hospitals and often require costly antifungals and intensive care. Chronic pulmonary aspergillosis usually involves prolonged oral azole therapy, particularly in patients with previous tuberculosis or chronic lung disease. Allergic bronchopulmonary aspergillosis is seen mainly in asthma and cystic fibrosis care.

 

Global estimates place chronic pulmonary aspergillosis incidence at approximately 1.84 million cases annually, with around 340,000 deaths. Allergic bronchopulmonary aspergillosis may affect 4.8 million adults with asthma, while approximately 1.2 million people are estimated to develop chronic pulmonary aspergillosis after tuberculosis.

Hospital spending, prolonged therapy, resistance, and access to testing will have a greater effect on revenue than prevalence estimates alone.

 

Invasive Aspergillosis Will Remain the Highest-Value Hospital Segment

Nearly 15,000 aspergillosis-associated hospitalizations occurred in the United States in 2014, generating an estimated USD 1.2 billion in hospital costs. Invasive aspergillosis-related admissions increased by an average of approximately 3% annually from 2000 to 2013.

Demand is concentrated among patients with hematologic malignancies, prolonged neutropenia, stem-cell transplantation, solid-organ transplantation, severe respiratory disease, and intensive immunosuppression. CDC has also noted that invasive Aspergillus risk has shifted as transplant volumes and the use of newer immunosuppressive medicines have increased.

Severe cases require antifungal therapy, fungal testing, intensive-care support, specialist input, and longer hospital stays. When diagnosis is delayed, patients may need more costly salvage treatment and remain in hospital for longer.

Invasive aspergillosis will remain the market’s highest-revenue treatment setting because mortality exposure and hospital intensity support premium drug and diagnostic spending.

 

Chronic Pulmonary Aspergillosis Creates Durable Oral-Azole Demand

Global chronic pulmonary aspergillosis incidence is estimated at approximately 1.84 million cases annually, with around 340,000 deaths. CDC-cited estimates indicate that about 1.2 million people develop the disease after tuberculosis.

A randomized study in chronic cavitary pulmonary aspergillosis found an overall response rate of 76.5% with itraconazole, compared with 35.7% in the control group.

The disease creates a different revenue profile from invasive aspergillosis. Treatment extends across several months and can involve repeated or suppressive therapy, supporting continuing demand for oral itraconazole and voriconazole.

Generic availability limits revenue per prescription, but the size and duration of the treated population preserve a substantial volume base. Chronic pulmonary aspergillosis will remain the main long-duration antifungal segment, particularly in countries with high tuberculosis and chronic lung-disease burdens.

 

ABPA Will Support Selective Respiratory-Specialty Treatment

Allergic bronchopulmonary aspergillosis may affect approximately 4.8 million adults with asthma worldwide, creating a sizeable potential population across respiratory and allergy practices.

The 2024 ISHAM-ABPA guidance supports oral prednisolone or itraconazole monotherapy for most acute cases. Combined treatment is mainly reserved for recurrent exacerbations, while asymptomatic disease is not routinely treated.

The updated guidance limits unnecessary antifungal exposure and narrows demand to symptomatic and recurrent disease. This reduces the likelihood that broad ABPA prevalence will convert directly into prescription volume.

ABPA will remain a meaningful outpatient market for itraconazole and corticosteroid-based care, but treatment revenue will be controlled by guideline-defined patient selection rather than total asthma-associated prevalence.

 

Established Azoles Will Retain the Treatment Base

Voriconazole produced 12-week survival of 70.8% in invasive aspergillosis, compared with 57.9% for amphotericin B in pivotal comparative evidence. This survival advantage established voriconazole as the reference treatment across hospital practice.

Posaconazole also demonstrated commercial value in prevention, reducing invasive aspergillosis among selected high-risk neutropenic patients from approximately 7% with fluconazole or itraconazole to around 1%.

Itraconazole remains important in chronic pulmonary disease and ABPA, while isavuconazole competes in hospital accounts where tolerability, drug interactions, or institutional protocols support an alternative triazole.

Established azoles will continue to control the largest treatment volume. Premium therapies will gain share primarily where resistance, toxicity, drug interactions, or treatment failure weaken the established azole options.

 

Azole Resistance Is Increasing Demand for Testing and Alternative Therapy

CDC reports that patients with azole-resistant Aspergillus fumigatus infection may be up to 33% more likely to die than patients with susceptible infections.

Some medical centres have reported resistance in approximately 19% of tested A. fumigatus infections. A large U.S. study detected resistance in up to 7% of Aspergillus specimens from stem-cell and solid-organ transplant recipients.

Resistance is not limited to patients with previous medical azole exposure. CDC has also linked resistant infections with environmental exposure to agricultural azole fungicides. U.S. Geological Survey estimates cited by CDC indicate that agricultural azole fungicide use quadrupled between 2013 and 2016.

These figures are changing hospital purchasing from broad azole use toward susceptibility-led treatment. Resistance will strengthen demand for diagnostics, liposomal amphotericin B, and novel non-azole agents while limiting confidence in empirical triazole use.

 

Diagnostic Approvals Are Moving Testing Closer to Treatment Revenue

The FDA granted 510(k) clearance to Pearl Diagnostics’ MycoMEIA Aspergillus Assay on August 1, 2025. The clearance added a regulated urine-based galactomannan test to the invasive aspergillosis diagnostic market.

The assay provides an additional diagnostic option for patients in whom standard sampling procedures are delayed, contraindicated, or difficult to obtain. Earlier identification of Aspergillus antigen may support timely antifungal treatment in patients with invasive disease and help avoid unnecessary therapy in those without evidence of infection.

WHO’s 2025 fungal diagnostic and treatment pipeline reports also identified limited access to rapid, affordable, and point-of-care testing as a major barrier, particularly in lower-resource health systems.

Diagnostic expansion will increase the number of patients who move from suspected disease into confirmed and targeted antifungal treatment. Test manufacturers will therefore capture a growing share of aspergillosis-related spending alongside drug suppliers.

 

Diagnostic Gaps Will Continue to Restrict Low-Income Market Conversion

WHO’s 2025 review found that rapid and affordable fungal tests remain limited in many lower-resource countries. Aspergillosis is particularly exposed because symptoms can overlap with tuberculosis, bacterial pneumonia, COPD exacerbation, malignancy, and severe viral respiratory disease.

South-East Asia was estimated to have approximately 145,372 chronic pulmonary aspergillosis cases following pulmonary tuberculosis in an earlier burden model. India-focused estimates place annual invasive aspergillosis incidence above 250,000 cases, largely associated with COPD and other high-risk populations.

Large epidemiological burdens will not convert fully into treatment revenue while fungal testing, specialist care, susceptibility testing, and therapeutic monitoring remain unavailable.

Low- and middle-income markets will expand mainly through wider diagnosis and affordable generic azoles. Premium antifungal launches alone will have limited impact without parallel investment in mycology infrastructure.

 

Transplant Prophylaxis Is Becoming More Selective

IDSA’s 2026 guidance suggests against routine universal anti-Aspergillus prophylaxis following liver transplantation and supports targeted use among selected high-risk patients.

Risk factors include peri-transplant renal replacement therapy, retransplantation, and transplantation for fulminant hepatic failure.

For lung transplantation, the 2026 update makes no recommendation for or against universal prophylaxis and no recommendation for or against targeted or pre-emptive approaches. This leaves treatment protocols dependent on individual transplant-centre practices and local epidemiology.

The shift toward risk-based prophylaxis will reduce blanket antifungal use while protecting demand in patients with the highest likelihood of infection. Suppliers will need strong evidence in defined transplant populations rather than relying on broad anti-mould positioning.

 

Olorofim Is the Leading Near-Term Pipeline Opportunity

WHO’s 2025 antifungal pipeline review identified 43 products in development as of September 30, 2024. The pipeline included 21 clinical-stage and 22 preclinical products. Only nine of the clinical-stage candidates were novel agents, while just four antifungals had received approval from a stringent regulatory authority during the previous decade.

F2G and Shionogi reported positive topline Phase 3 OASIS results for olorofim in June 2026. The study enrolled invasive aspergillosis patients who had failed or could not use azole therapy.

Day-42 all-cause mortality reached 23.8% with olorofim, compared with 24.3% for liposomal amphotericin B followed by standard care, meeting the non-inferiority objective. Drug-related treatment-emergent adverse events occurred in 35.8% of olorofim-treated patients and 63.9% of comparator patients.

F2G also secured USD 100 million in financing in 2024 from investors including the AMR Action Fund. The funding and Phase 3 results give olorofim the strongest late-stage commercial position among novel aspergillosis therapies.

Approval would initially position olorofim in azole-resistant, azole-intolerant, and refractory disease. Wider use will depend on final regulatory review, pricing, and full clinical-response evidence.

 

Opelconazole’s Phase 3 Termination Raises the Development Barrier

Pulmocide terminated the Phase 3 OPERA-T study of inhaled opelconazole in January 2026 after an interim analysis found a numerically lower favourable response and numerically higher mortality in the opelconazole group.

The study involved severely immunocompromised patients with refractory invasive pulmonary aspergillosis, including patients with hematologic malignancies, transplant history, and previous treatment failure.

The termination limits near-term competition in inhaled antifungal development and highlights the challenge of improving outcomes in refractory invasive aspergillosis.

Opelconazole’s setback improves olorofim’s relative pipeline position, but it also raises the evidence threshold for future therapies targeting heavily treated invasive aspergillosis patients.

 

The United States Will Remain the Highest-Value Treatment Market

The U.S. EHR study covering more than 76 million adults found that recorded aspergillosis prevalence increased by approximately 5% annually from 2013 to 2023.

Historical hospitalization costs reached USD 1.2 billion from nearly 15,000 aspergillosis-associated admissions in 2014. The United States also has large transplant, oncology, ICU, and specialist pulmonary populations supported by advanced diagnostics and reimbursement for premium antifungals.

The market can support branded triazoles, liposomal amphotericin B, diagnostics, therapeutic monitoring, and future novel agents at a level that is difficult to match in lower-resource health systems.

The United States will continue to generate the highest revenue per treated patient. Growth will be led by high-risk hospital populations, resistance testing, and the adoption of new therapies for azole-limited disease.

 

Europe Will Be a Resistance- and Stewardship-Led Market

European hospitals have placed sustained attention on azole-resistant A. fumigatus because resistance can arise through both medical antifungal exposure and environmental fungicide use.

Reports of resistance approaching 19% at some medical centres increase the importance of local surveillance and susceptibility-led treatment. European health systems are also more likely to evaluate new agents through hospital budget impact, toxicity, resistant-disease need, and comparative clinical outcomes.

Premium antifungals will face strict reimbursement scrutiny, but products addressing verified resistance or reducing hospital toxicity can gain a stronger formulary position.

Europe will remain a high-value but controlled market. Diagnostics and resistance evidence will have greater influence over drug adoption than broad prescribing familiarity.

 

Asia-Pacific Will Lead Burden but Remain Price Sensitive

South-East Asia was estimated to have 145,372 chronic pulmonary aspergillosis cases after pulmonary tuberculosis in an earlier regional model. India-focused estimates place annual invasive aspergillosis incidence above 250,000 cases.

The region also has large COPD, tuberculosis, asthma, transplant, hematology, and diabetes populations. However, access to fungal diagnostics, specialist care, susceptibility testing, newer triazoles, and liposomal amphotericin B remains highly uneven.

Generic itraconazole and voriconazole will continue to account for most treatment volume in high-burden countries. Premium products will remain concentrated in major urban hospitals, transplant centres, and privately funded care.

Asia-Pacific will provide the largest long-term patient opportunity, but revenue growth will depend more on diagnostic expansion and affordable treatment than on rapid uptake of high-priced novel agents.

 

Supplier Positioning Will Divide by Treatment Setting

Voriconazole retains the strongest first-line hospital position, supported by its 70.8% 12-week survival result compared with 57.9% for amphotericin B. Isavuconazole will compete in hospital accounts where tolerability and treatment compatibility support premium use.

Posaconazole will remain important in high-risk hematology prophylaxis after reducing invasive aspergillosis from approximately 7% to 1% in comparative evidence. Itraconazole will retain substantial outpatient volume through chronic pulmonary aspergillosis and ABPA.

Liposomal amphotericin B will remain essential where azoles cannot be used or resistance is suspected. Olorofim could enter this high-value segment if regulatory review confirms the Phase 3 benefit-risk profile.

The market is likely to remain segmented across established azoles used at scale, higher-cost hospital therapies, and treatments for resistant or refractory disease. Commercial uptake will depend on where each product fits within routine prescribing, hospital formularies, and resistance-management pathways.

 

Strategic Outlook: Diagnostics and Resistance Coverage Will Decide Future Growth

Recorded aspergillosis prevalence increased by approximately 5% annually in the large U.S. EHR study, while invasive disease already produces substantial hospital costs and chronic disease supports prolonged outpatient treatment.

Azoles will remain the treatment foundation because voriconazole, itraconazole, and posaconazole have established evidence, generic availability, and broad clinical familiarity. However, resistance rates of up to 19% at some centres and mortality risk up to 33% higher in resistant infection are increasing demand for alternative therapy.

Pearl Diagnostics’ 2025 MycoMEIA clearance strengthens the diagnostic market, while IDSA’s 2026 transplant guidance shifts prophylaxis toward more selective use. F2G and Shionogi’s positive OASIS results position olorofim as the main near-term pipeline event, while the termination of Pulmocide’s OPERA-T study reduces late-stage competition.

The strongest market growth through 2032 will come from faster diagnosis, susceptibility-led prescribing, expanded chronic pulmonary treatment, and new options for azole-resistant or azole-intolerant disease. Suppliers that align treatment evidence with diagnostic confirmation and hospital stewardship will hold stronger commercial positions than products competing only on broad antifungal coverage.

 

Aspergillosis Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.3 Billion
Revenue Forecast in 2032	USD 6.17 Billion
Overall Growth Rate	CAGR of 5.27% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Disease Type, By Treatment Type, By End User, By Geography
By Disease Type	Invasive Aspergillosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
By Treatment Type	Triazole Antifungals, Polyenes, Echinocandins and Combination/Salvage Therapy, Corticosteroid-Based ABPA Therapy, Emerging Antifungal Therapies
By End User	Hospitals, Transplant and Oncology Centers, Pulmonary and Respiratory Specialty Clinics, Infectious Disease Specialty Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Rising invasive aspergillosis cases among immunocompromised patients, increasing antifungal resistance, growing demand for rapid fungal diagnostics, expansion of transplant and oncology care, and adoption of targeted antifungal therapies
Customization Option	Available upon request